AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39129921 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels in cord blood
Number of subjects: 140
Study 39130023 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) detectable in 80.7% of patients; median hs-cTnT 10 ng/L (IQR: 6-18 ng/L)
Number of subjects: 1687
Study 39130025 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy for AF in cancer patients
Number of subjects: 1514
Study 39130048 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently high hs-CRP
Number of subjects: 10460
Study 39130048 — intervention group
Group type: COMPARATOR
Intervention: Persistently low hs-CRP
Number of subjects: 10460
Study 39130048 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated (increased) hs-CRP
Number of subjects: 10460
Study 39130048 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced hs-CRP
Number of subjects: 10460
Study 39130140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL) as an adjunct to coronary stenting
Number of subjects: 0
Study 39130192 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioecological factors (environmental, interpersonal, and individual)
Number of subjects: 0
Study 39130192 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in eating behaviors (EB) and physical activity (PA)
Number of subjects: 0
Study 39130760 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model for predicting Endoscopic Mayo Score (eMS)
Number of subjects: 249
Study 39130768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-to-moderate COVID-19 patients
Number of subjects: 110
Study 39130768 — intervention group
Group type: COMPARATOR
Intervention: Severe COVID-19 patients
Number of subjects: 110
Study 39131140 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 75 mg/day
Number of subjects: 25
Study 39131140 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 50 mg/day
Number of subjects: 25
Study 39131140 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 25 mg/day
Number of subjects: 25
Study 39131144 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 8 mg insulin
Number of subjects: 32
Study 39131144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 39131150 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen via nonrebreather mask
Number of subjects: 8
Study 39131473 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella-supported HRPCI
Number of subjects: 406
Study 39131473 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization during HRPCI
Number of subjects: 406
Study 39131596 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic drainage (DG)
Number of subjects: 232
Study 39131596 — intervention group
Group type: COMPARATOR
Intervention: Non-drainage (NDG)
Number of subjects: 232
Study 39131668 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam administered with mixed meal tests
Number of subjects: 12
Study 39131668 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12
Study 39131668 — intervention group
Group type: EXPERIMENTAL
Intervention: BAM patients without colesevelam
Number of subjects: 12
Study 39131711 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 600-mg induction therapy
Number of subjects: 527
Study 39131711 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (various doses)
Number of subjects: 527
Study 39131711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study 39131784 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy with the ClotTriever System
Number of subjects: 500
Study 39132049 — intervention group
Group type: COMPARATOR
Intervention: Canocapavir 25 mg
Number of subjects: 64
Study 39132049 — intervention group
Group type: COMPARATOR
Intervention: Canocapavir 75 mg
Number of subjects: 64
Study 39132049 — intervention group
Group type: COMPARATOR
Intervention: Canocapavir 150 mg
Number of subjects: 64
Study 39132049 — intervention group
Group type: COMPARATOR
Intervention: Canocapavir 300 mg
Number of subjects: 64
Study 39132049 — intervention group
Group type: COMPARATOR
Intervention: Canocapavir 450 mg
Number of subjects: 64
Study 39132049 — intervention group
Group type: COMPARATOR
Intervention: Canocapavir 75 mg (multiple ascending dose)
Number of subjects: 64
Study 39132049 — intervention group
Group type: COMPARATOR
Intervention: Canocapavir 150 mg (multiple ascending dose)
Number of subjects: 64
Study 39132049 — intervention group
Group type: COMPARATOR
Intervention: Canocapavir 300 mg (multiple ascending dose)
Number of subjects: 64
Study 39132049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 39132068 — intervention group
Group type: EXPERIMENTAL
Intervention: LCR1-LCR2
Number of subjects: 3520
Study 39132075 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-residue diet (LRD) (<10 g fiber per day)
Number of subjects: 28
Study 39132075 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-residue diet (LRD)
Number of subjects: 28
Study 39132187 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription Digital Therapeutic (PDT) containing cognitive behavioral therapy for 90 days
Number of subjects: 22
Study 39132335 — intervention group
Group type: EXPERIMENTAL
Intervention: One-month dual antiplatelet therapy (DAPT)
Number of subjects: 273
Study 39132335 — intervention group
Group type: COMPARATOR
Intervention: Non-Asian cohort
Number of subjects: 273
Study 39132368 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus target-eluting stent
Number of subjects: 196
Study 39132368 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent
Number of subjects: 196
Study 39132396 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella and Saranas Early Bird Bleed Monitoring System (EBBMS)
Number of subjects: 184
Study 39132400 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture-mediated closure using the Aortix pMCS device
Number of subjects: 21
Study 39132400 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized steps for suture-mediated closure
Number of subjects: 21
Study 39132473 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 session of multi-voxel neuro-reinforcement
Number of subjects: 23
Study 39132473 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sessions of multi-voxel neuro-reinforcement
Number of subjects: 23
Study 39132473 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 sessions of multi-voxel neuro-reinforcement
Number of subjects: 23
Study 39132473 — intervention group
Group type: COMPARATOR
Intervention: Control phobia (not specified intervention)
Number of subjects: 23
Study 39132483 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level intervention
Number of subjects: 629
Study 39132523 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk pulmonary embolism patients
Number of subjects: 1517
Study 39132922 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated contoured foot orthoses
Number of subjects: 27
Study 39132922 — intervention group
Group type: COMPARATOR
Intervention: Flat shoe inserts
Number of subjects: 27
Study 39132937 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 0
Study 39132937 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 0
Study 39132946 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices (MAPs)
Number of subjects: 247
Study 39132946 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivorship Education (SE)
Number of subjects: 247
Study 39132946 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 247
Study 39132982 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine regimen 1
Number of subjects: 0
Study 39132982 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine regimen 2
Number of subjects: 0
Study 39132982 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine regimen 3
Number of subjects: 0
Study 39132982 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 39133200 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 207
Study 39133200 — intervention group
Group type: COMPARATOR
Intervention: secukinumab 150 mg
Number of subjects: 207
Study 39133306 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab and nivolumab
Number of subjects: 100
Study 39133438 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue scale
Number of subjects: 586
Study 39133438 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue score increase
Number of subjects: 586
Study 39133438 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue score change
Number of subjects: 586
Study 39133438 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue score severity bands
Number of subjects: 586
Study 39133474 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral apixaban, 5 mg (or 2.5 mg if criteria met), twice daily
Number of subjects: 1015
Study 39133474 — intervention group
Group type: COMPARATOR
Intervention: Oral aspirin, 81 mg, once daily
Number of subjects: 1015
Study 39133474 — intervention group
Group type: COMPARATOR
Intervention: Comparison of apixaban vs aspirin among those with cancer
Number of subjects: 1015
Study 39133505 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC
Number of subjects: 1305
Study 39133505 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1305
Study 39133532 — intervention group
Group type: EXPERIMENTAL
Intervention: HOLA intervention
Number of subjects: 30
Study 39133680 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized pain medication tapering program
Number of subjects: 195
Study 39133680 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized pain medication tapering program
Number of subjects: 195
Study 39133680 — intervention group
Group type: COMPARATOR
Intervention: No tapering program
Number of subjects: 195
Study 39133774 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1 Blockade with RPH-104 (Goflikicept)
Number of subjects: 0
Study 39133774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39133806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib plus nivolumab and ipilimumab (CaboNivoIpi)
Number of subjects: 11
Study 39133883 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA2 carriers
Number of subjects: 40
Study 39133883 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA7 carriers
Number of subjects: 40
Study 39133883 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 40
Study 39133915 — intervention group
Group type: EXPERIMENTAL
Intervention: EMA design factors (number of questions per survey, number of EMAs per day, EMA prompting schedule, payment type, EMA response scale type)
Number of subjects: 411
Study 39133915 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults, those without a history of substance use problems, and those without current depression
Number of subjects: 411
Study 39133915 — intervention group
Group type: EXPERIMENTAL
Intervention: App usability
Number of subjects: 411
Study 39133915 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall EMA completion
Number of subjects: 411
Study 39133921 — intervention group
Group type: EXPERIMENTAL
Intervention: venetoclax-azacitidine
Number of subjects: 392
Study 39133921 — intervention group
Group type: COMPARATOR
Intervention: placebo-azacitidine
Number of subjects: 392
Study 39133923 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior SARS-CoV-2 infection
Number of subjects: 10094
Study 39133923 — intervention group
Group type: COMPARATOR
Intervention: Uninfected participants
Number of subjects: 10094
Study 39133923 — intervention group
Group type: EXPERIMENTAL
Intervention: PASC index ≥12
Number of subjects: 10094
Study 39133923 — intervention group
Group type: COMPARATOR
Intervention: PASC index = 0
Number of subjects: 10094
Study 39134021 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined movements in parietal cortex
Number of subjects: 0
Study 39134085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraurethral LBP-EC01 (2 days) and intravenous LBP-EC01 (1×10) for 3 days
Number of subjects: 39
Study 39134086 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive radiotherapy (up to 74 Gy)
Number of subjects: 158
Study 39134086 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (66 Gy)
Number of subjects: 158
Study 39134120 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab (anti-CD38 monoclonal antibody)
Number of subjects: 26
Study 39134120 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab (anti-CD38 monoclonal antibody)
Number of subjects: 26
Study 39134144 — intervention group
Group type: EXPERIMENTAL
Intervention: Decídetexto
Number of subjects: 457
Study 39134144 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 457
Study 39134156 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 67
Study 39134156 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSR
Number of subjects: 67
Study 39134346 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant anti-PD-1 therapy
Number of subjects: 0
Study 39134346 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockade of TIM-3 and PD-1
Number of subjects: 0
Study 39134346 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement of anti-TIM-3
Number of subjects: 0
Study 39134346 — intervention group
Group type: COMPARATOR
Intervention: Tumor and paired lung samples from treatment-naïve patients
Number of subjects: 0
Study 39134391 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping infliximab
Number of subjects: 202
Study 39134391 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker pairs (top 10)
Number of subjects: 202
Study 39134434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sesame oral immunotherapy (OIT) with a 300 mg maintenance dose of sesame protein administered once daily for up to 18 months
Number of subjects: 39
Study 39134434 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment including an elimination diet and observation for 1 year
Number of subjects: 39
Study 39134434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sesame oral immunotherapy (OIT)
Number of subjects: 39
Study 39134434 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment including an elimination diet
Number of subjects: 39
Study 39134435 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal microbiome analysis
Number of subjects: 400
Study 39134435 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome dynamics assessment using 16S and 18S rDNA surveys
Number of subjects: 400
Study 39134435 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of maternal weight in first and third trimesters
Number of subjects: 400
Study 39134435 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of birth outcomes
Number of subjects: 400
Study 39134435 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant growth and nutritional parameters using WHO z-scores
Number of subjects: 400
Study 39134435 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient analysis in serum using metallomics
Number of subjects: 400
Study 39134435 — intervention group
Group type: EXPERIMENTAL
Intervention: Macronutrient analysis in stool
Number of subjects: 400
Study 39134435 — intervention group
Group type: EXPERIMENTAL
Intervention: Metatranscriptomics and metabolomics
Number of subjects: 400
Study 39134437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgical care journey narrative inquiry
Number of subjects: 16
Study 39134437 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Experience Measures and Patient-Reported Outcome Measures
Number of subjects: 16
Study 39134444 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuasive health communication intervention (PHCI) delivered by video
Number of subjects: 0
Study 39134444 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuasive health communication intervention (PHCI) delivered in person
Number of subjects: 0
Study 39134444 — intervention group
Group type: COMPARATOR
Intervention: Current practice
Number of subjects: 0
Study 39134444 — intervention group
Group type: EXPERIMENTAL
Intervention: PHCI video with captions
Number of subjects: 0
Study 39134444 — intervention group
Group type: EXPERIMENTAL
Intervention: PHCI video without captions
Number of subjects: 0
Study 39134529 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib plus gefitinib
Number of subjects: 315
Study 39134529 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus anlotinib
Number of subjects: 315
Study 39134529 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib plus placebo
Number of subjects: 315
Study 39134652 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for ≤35 cycles with ongoing enzalutamide until progression, unacceptable toxicity, or withdrawal (C4)
Number of subjects: 126
Study 39134652 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for ≤35 cycles with ongoing enzalutamide until progression, unacceptable toxicity, or withdrawal (C5)
Number of subjects: 126
Study 39134652 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for ≤35 cycles with ongoing enzalutamide until progression, unacceptable toxicity, or withdrawal (C4 and C5 combined)
Number of subjects: 126
Study 39134667 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk (2 ml orally)
Number of subjects: 90
Study 39134667 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 39134699 — intervention group
Group type: EXPERIMENTAL
Intervention: Oswestry Disability Index (ODI)
Number of subjects: 601
Study 39134699 — intervention group
Group type: EXPERIMENTAL
Intervention: Zürich Claudication Questionnaire (ZCQ)
Number of subjects: 601
Study 39134699 — intervention group
Group type: COMPARATOR
Intervention: Global Perceived Effect scale (GPE)
Number of subjects: 601
Study 39134784 — intervention group
Group type: EXPERIMENTAL
Intervention: ObsQoR-10 at 24 hr postpartum
Number of subjects: 222
Study 39134784 — intervention group
Group type: EXPERIMENTAL
Intervention: ObsQoR-10 breastfeeding sub-score at 24 hr
Number of subjects: 222
Study 39134868 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training for 4 weeks followed by telephone counselling for 4 weeks
Number of subjects: 52
Study 39134959 — intervention group
Group type: COMPARATOR
Intervention: CEM (Carboplatin, Etoposide, Melphalan)
Number of subjects: 58
Study 39134986 — intervention group
Group type: EXPERIMENTAL
Intervention: Holotranscobalamin (HTC) concentration
Number of subjects: 99
Study 39134986 — intervention group
Group type: EXPERIMENTAL
Intervention: Total vitamin B12 (B12) concentration
Number of subjects: 99
Study 39134986 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylmalonic acid (MMA) concentration
Number of subjects: 99
Study 39135010 — intervention group
Group type: EXPERIMENTAL
Intervention: CHALLENGE intervention (experimental arm)
Number of subjects: 300
Study 39135010 — intervention group
Group type: COMPARATOR
Intervention: Activity monitor-only intervention (comparison arm)
Number of subjects: 300
Study 39135067 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal brain scan
Number of subjects: 403
Study 39135067 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched with NHDS data
Number of subjects: 403
Study 39135067 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched with NAB data
Number of subjects: 403
Study 39135067 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched with LP biomarker data
Number of subjects: 403
Study 39135126 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronate (1 mg/day)
Number of subjects: 72
Study 39135126 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (10 mg/day)
Number of subjects: 72
Study 39135209 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal/stem cells (MSCs) therapy
Number of subjects: 20
Study 39135209 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study 39135298 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Empowerment Program
Number of subjects: 0
Study 39135298 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39135452 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib treatment from baseline to week 18
Number of subjects: 166
Study 39135452 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib treatment
Number of subjects: 166
Study 39135540 — intervention group
Group type: EXPERIMENTAL
Intervention: Efzimfotase alfa (15 mg, 45 mg, or 90 mg) administered as one intravenous (i.v.) dose followed by 3 weekly subcutaneous (s.c.) doses.
Number of subjects: 15
Study 39135926 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement of trained religious leaders in maternal health education
Number of subjects: 593
Study 39135926 — intervention group
Group type: COMPARATOR
Intervention: Regular maternal health information (Control)
Number of subjects: 593
Study 39136011 — intervention group
Group type: COMPARATOR
Intervention: Zerafil (omalizumab biosimilar) administered at a dose ranging from 150 to 375 mg based on pre-treatment serum total IgE level and body weight every two or four weeks for 28 weeks.
Number of subjects: 0
Study 39136011 — intervention group
Group type: COMPARATOR
Intervention: Omalizumab (reference product) administered at a standard dose.
Number of subjects: 0
Study 39136011 — intervention group
Group type: COMPARATOR
Intervention: Zerafil (omalizumab biosimilar)
Number of subjects: 0
Study 39136011 — intervention group
Group type: COMPARATOR
Intervention: Zerafil (omalizumab biosimilar) and Omalizumab (reference product)
Number of subjects: 0
Study 39136260 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 40
Study 39136260 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily headache diary
Number of subjects: 40
Study 39136403 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride-glucose (TyG) index
Number of subjects: 1332
Study 39136560 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective prostatic arterial administration of gallium 68 PSMA PET/CT radioligand
Number of subjects: 0
Study 39136560 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of gallium 68 PSMA PET/CT radioligand
Number of subjects: 0